MedTrace Logo

Study of TGM-312-SC01 in Healthy Participants and Adults With MASH

NCT07427680 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2026-05-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Conditions

  • Healthy Participants
  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Interventions

DRUG

TGM-312-SC01

TGM-312-SC01 is an investigational medicinal product administered by subcutaneous injection according to a protocol-defined regimen.

DRUG

Placebo

Placebo administered by subcutaneous injection according to a protocol-defined regimen.

Sponsors & Collaborators

  • Tangram Therapeutics Plc

    lead INDUSTRY

Principal Investigators

  • Sponsor Medical Representative · Tangram Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-03
Primary Completion
2028-03-31
Completion
2028-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07427680 on ClinicalTrials.gov